Ardelyx, Inc. (NASDAQ:ARDX) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET
Company Participants
Caitlin Lowie - VP, Corporate Communications and IR
Mike Raab - President and CEO
Justin Renz - CFO
Susan Rodriguez - CCO
Rob Blanks - Chief Regulatory Affairs and Quality Assurance Officer
Conference Call Participants
Laura Chico - Wedbush Securities
Yigal Nochomovitz - Citi
Peyton Bohnsack - TD Cowen
Operator
Good afternoon everyone and welcome to the Ardelyx Fourth Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, today's event is being recorded.
And at this time, I'd like to turn the floor over to Caitlin Lowie, Vice President, Corporate Communications and Investor Relations. You may begin.
Caitlin Lowie
Thank you. Good afternoon everyone and welcome to our fourth quarter financial results call. During this call, we will refer to the press release issued earlier today, which is available in the Investors section of the company’s website at ardelyx.com.
During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to review our risk factors in our most recent annual report on Form 10-K filed today, which can also be found on our website at ardelyx.com. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.
Our President and CEO, Mike Raab will begin today's call with opening remarks and an overview of the company's progress during 2022 with a look ahead to 2023.
Next, Susan Rodriguez, Chief Commercial Officer, will provide an update on the launch of IBSRELA, as well as preparation activities to support successful launch of XPHOZAH if approved.
Justin Renz, Chief Financial and Operations Officer, will conclude today's formal remarks with a review of the company's financial performance during the fourth quarter and full year ended December 31st, 2022.
Dr. Laura Williams, Chief Medical Officer; Dr. David Rosenbaum, Chief Development Officer; and Rob Blanks, Chief Regulatory Affairs and Quality Assurance Officer will join us for the question-and-answer session period.
With that, let me pass the call over to Mike.
Mike Raab
Thank you, Caitlin and good afternoon everyone. It is a great pleasure that I provide an update on our IBSRELA launch and the tremendous progress that we have made on our path to bring XPHOZAH to the patients on dialysis.